Imaging Diagnostic Submits First Interim Report to FDA

FORT LAUDERDALE, Fla., Mar. 24 -- Imaging Diagnostic Systems Inc. has submitted to the US Food and Drug Administration an interim report on ongoing clinical investigation trials involving its laser-based breast imaging device, the CTLM. The CTLM utilizes laser technology and patented computed algorithms to create contiguous cross-sectional slice images of the breast without the use of breast compression or x-rays.
The report contains statistical results as well as comparative mammography and CTLM images of malignant and benign case studies. The case studies were acquired from Imaging Diagnostic's clinical sites, Nassau County Medical Center and the University of Virginia Hospital.